Zobrazeno 1 - 10
of 20
pro vyhledávání: '"B. G. Weinshenker"'
Autor:
S. Jarius, F. Paul, O. Aktas, N. Asgari, R. C. Dale, J. de Seze, D. Franciotta, K. Fujihara, A. Jacob, H. J. Kim, I. Kleiter, T. Kümpfel, M. Levy, J. Palace, K. Ruprecht, A. Saiz, C. Trebst, B. G. Weinshenker, B. Wildemann
Publikováno v:
Journal of Neuroinflammation, Vol 15, Iss 1, Pp 1-10 (2018)
Abstract Over the past few years, new-generation cell-based assays have demonstrated a robust association of autoantibodies to full-length human myelin oligodendrocyte glycoprotein (MOG-IgG) with (mostly recurrent) optic neuritis, myelitis and brains
Externí odkaz:
https://doaj.org/article/1dfbca0b7d634be58a08cea01226cdfb
Autor:
B G, Weinshenker, D M, Wingerchuk
Publikováno v:
Current topics in microbiology and immunology. 318
Neuromyelitis optica (NMO) is a severe demyelinating disease of the CNS that preferentially affects the optic nerves and spinal cord, tends to relapse, and results in early permanent disability for most affected patients. A new autoantibody marker ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::488a97dd604b15b83f6e4010b5a611e2
https://pubmed.ncbi.nlm.nih.gov/18219825
https://pubmed.ncbi.nlm.nih.gov/18219825
Publikováno v:
Neurology. 77:195-196
{#article-title-2} To the Editor: Shimizu et al.1 report increased demyelination and inflammation following interferon-β-1b (IFNβ-1b) therapy in patients with opticospinal multiple sclerosis (OSMS) and neuromyelitis optica (NMO). In the accompanyin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::64d538c8d24645eb53cc5cb849e37f9a
https://doi.org/10.1212/wnl.0b013e318219dde5
https://doi.org/10.1212/wnl.0b013e318219dde5
Autor:
D M, Wingerchuk, B G, Weinshenker
Publikováno v:
Neuroimaging clinics of North America. 10(4)
Advances in MR imaging and randomized controlled-trial methodology have fundamentally altered the diagnosis and investigation of multiple sclerosis (MS). Further progress in epidemiology and classification will provide clues toward identification of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a8d28f5dc888866e211529ed548d5eb9
https://pubmed.ncbi.nlm.nih.gov/11359715
https://pubmed.ncbi.nlm.nih.gov/11359715
Autor:
B. G. Weinshenker, J. H. Noseworthy
Publikováno v:
Clinical Trials in Neurology ISBN: 9781849968560
Rapid growth in the number, scale and quality of clinical trials in multiple sclerosis (MS) has occurred over the last decade. The recent surge of interest has resulted from a number of developments. Firstly, basic scientific inquiry in such areas as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::840096e8ca565506050afba6422ccdc8
https://doi.org/10.1007/978-1-4471-3787-0_31
https://doi.org/10.1007/978-1-4471-3787-0_31
Autor:
J H, Noseworthy, P C, O'Brien, B G, Weinshenker, J A, Weis, T M, Petterson, B J, Erickson, A J, Windebank, J P, Whisnant, K A, Stolp-Smith, C M, Harper, P A, Low, L J, Romme, M, Johnson, K N, An, M, Rodriguez
Publikováno v:
Neurology. 55(8)
Immunoglobulin (Ig) administration induces remyelination in the Theiler's virus model of MS.A randomized, double-blinded, placebo-controlled trial of IV immunoglobulin (IVIg) was performed in patients with MS who had persistent muscle weakness that h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::31618778e0ecb46211fd545f6b95775a
https://pubmed.ncbi.nlm.nih.gov/11071491
https://pubmed.ncbi.nlm.nih.gov/11071491
Publikováno v:
Neurology. 73:1604-1605
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::523caec426dcbafc4f9f09005c68786c
https://doi.org/10.1212/wnl.0b013e3181bd6a85
https://doi.org/10.1212/wnl.0b013e3181bd6a85
Autor:
B G, Weinshenker
Publikováno v:
Journal of clinical apheresis. 14(3)
Idiopathic inflammatory demyelinating diseases (IIDDs) of the central nervous system, of which multiple sclerosis is the prototype, represent a family of monophasic, recurrent or progressive diseases with overlapping clinical and pathological manifes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::417aca25984e53673b1ab14e5d54d44c
https://pubmed.ncbi.nlm.nih.gov/10540370
https://pubmed.ncbi.nlm.nih.gov/10540370
Autor:
B G, Weinshenker, P C, O'Brien, T M, Petterson, J H, Noseworthy, C F, Lucchinetti, D W, Dodick, A A, Pineda, L N, Stevens, M, Rodriguez
Publikováno v:
Annals of neurology. 46(6)
There are no established treatments for patients with acute, severe neurological deficits caused by multiple sclerosis or other inflammatory demyelinating diseases of the central nervous system who fail to recover after treatment with high-dose corti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::17bb820e7723fcdc994aaf8ec0fb4213
https://pubmed.ncbi.nlm.nih.gov/10589540
https://pubmed.ncbi.nlm.nih.gov/10589540
Autor:
B. G. Weinshenker, A. Jacob, I. Kister, J. Herbert, M. L. Swerdlow, R. Bergamaschi, G. Piccolo, J. Oger, K. Ikeda, Y. Araki, Y. Iwasaki, I . Kister, J . Herbert, M .L. Swerdlow, R . Bergamaschi, G . Piccolo, J . Oger, M. Gotkine, O. Abramsky
Publikováno v:
Neurology. 68:1326-1327
An increased incidence of multiple sclerosis (MS) has been reported in patients with myasthenia gravis (MG). We reviewed records of 214 patients with MG. CNS demyelinating disease (CNSDD) occurred in five patients (2.3%). CNSDD always occurred after
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ff098a63f64b35c9bb05e92d11a60b65
https://doi.org/10.1212/01.wnl.0000262954.51568.25
https://doi.org/10.1212/01.wnl.0000262954.51568.25